Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study
Authors:
- Katarzyna Pawińska-WąsikowskaKPKatarzyna Pawińska-Wąsikowska
- Małgorzata CzogałaMCMałgorzata Czogała
- Karolina Bukowska-StrakovaKBKarolina Bukowska-Strakova
- Teofila KsiążekTKTeofila Książek
- Agnieszka PacAPAgnieszka Pac
- Magdalena SamborskaMSMagdalena Samborska
- Jacek WachowiakJWJacek Wachowiak
- Anna TomońATAnna Tomoń
- Radosław ChaberRCRadosław Chaber
- Karolina ZielezińskaKZKarolina Zielezińska
- Tomasz UrasińskiTUTomasz Urasiński
- Anna Rodziewicz-KonarskaARAnna Rodziewicz-Konarska
Open Access
- 28 September 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7548
Abstract
Background: Significant progress has been achieved in the treatment of children with myeloid leukemia associated with Down syndrome (ML-DS). We aimed to evaluate treatment outcomes and prognostic factors in children with ML-DS treated in Poland. Methods: Thirty-six children with ML-DS treated at pediatric hematology and oncology centers in Poland according to the ML-DS 2006 protocol based on the AML-BFM backbone between 2015 and 2024 were retrospectively analyzed. Results: The estimated 5-year event-free survival (EFS) and overall survival (OS) were 84.3% (95%CI: 72.5–98.1%) and 87.9% (77.4–99.8%), respectively. Although children with a complex karyotype showed numerically lower survival estimates than those with isolated constitutional trisomy 21 or additional cytogenetic abnormalities (OS: 60% [95%CI: 29.3–100%] vs. 90% [73.2–100%] vs. 92.3% [78.9–100%], p = 0.24; EFS: 60% [95%CI: 29.3–100%) vs. 75% [49.6–100%] vs. 92.3% [78.9–100%], p = 0.26), p = 0.26), these differences were not statistically significant. MRD positivity (≥0.1%) after the second induction cycle was identified as an adverse prognostic factor in the univariable analysis (HR = 31.1, 95%CI: 2.74–353.2; p = 0.006). Conclusions: Persistent MRD positivity after the second induction cycle may identify children with ML-DS at increased risk of treatment failure. Larger multicenter studies are needed to validate the prognostic significance of MRD and recurrent molecular alterations to optimize risk-adapted treatment strategies.Keywords
This publication has 25 references indexed in Scilit:
- Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndromePediatric Blood & Cancer, 2024
- Clinical and biological aspects of myeloid leukemia in Down syndromeLeukemia, 2021
- Treatment of acute myeloid leukemia in children: A practical perspectivePediatric Blood & Cancer, 2021
- Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndromeNature Communications, 2021
- Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemiaScientific Reports, 2020
- Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in JapanPediatric Blood & Cancer, 2015
- Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced‐dose chemotherapy on Children's Oncology Group trial A2971Cancer, 2012
- Continuous and high‐dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down studyPediatric Blood & Cancer, 2010
- Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literatureAnnals of Hematology, 2006
- Mutation analysis of SBDS in pediatric acute myeloblastic leukemiaPediatric Blood & Cancer, 2005